Journal of Clinical Endocrinology & Metabolism, Vol 59, 1006-1010, Copyright © 1984 by Endocrine Society

ARTICLES

Effects of human pancreatic growth hormone-releasing factor-40 on serum growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone, and somatomedin-C concentrations in normal women throughout the menstrual cycle

WS Evans, JL Borges, ML Vance, DL Kaiser, AD Rogol, R Furlanetto, J Rivier, W Vale and MO Thorner

Human pancreatic tumor GH-releasing factor-40 (hpGRF-40) selectively stimulates GH secretion in normal men and in some adults with GH deficiency. To study its effects in women, we administered hpGRF-40 (3.33 micrograms/kg) or an equivalent volume of vehicle as an iv bolus at 0900 h to 10 normal women during the early follicular, late follicular, and midluteal phases of the menstrual cycle. Serum concentrations of GH, PRL, LH, and FSH were measured at intervals between 0800-1100 h. Serum somatomedin-C concentrations were measured before and 24 h after the administration of vehicle of hpGRF-40. Within 1-3 min after the injection of hpGRF-40 all women described warmth localized to the head and neck and exhibited facial flushing. No changes in pulse rate or blood pressure were noted. When expressed as change from baseline and compared to control values, peak levels of serum GH (nanograms per ml; mean +/- SEM) were higher after hpGRF-40 treatment during the early follicular (5.4 +/- 3.2 vs. 34.9 +/- 8.3; control vs. test day; P = 0.011), late follicular (5.6 +/- 1.5 vs. 25.2 +/- 6.8; P = 0.014), and luteal (0.8 +/- 1.0 vs. 32.7 +/- 12.8; P = 0.033) phases of the menstrual cycle. Similarly, integrated serum GH levels (nanograms per ml/h) were higher after hpGRF-40 administration during the early follicular (0.72 vs. 16.1; P = 0.011), late follicular (0.83 vs. 9.9; P = 0.037), and luteal (-1.54 vs. 17.0; P = 0.036) phases of the cycle. When the increases in serum GH after hpGRF-40 treatment were compared among the phases of the menstrual cycle, however, no differences were found. Serum somatomedin-C values 24 h after hpGRF-40 treatment were higher than those 24 h after vehicle at all stages of the menstrual cycle. hpGRF-40 did not stimulate the release of PRL, LH, or FSH. We conclude that hpGRF-40 stimulates the release of GH, but that in response to the dose used, hpGRF-40- stimulated GH release does not vary during the menstrual cycle.

This article has been cited by other articles:

				A. Wieck, R. A. Davies, A. D. Hirst, N. Brown, A. Papadopoulos, M. N. Marks, S. A. Checkley, R. C. Kumar, and I. C. Campbell Menstrual Cycle Effects on Hypothalamic Dopamine Receptor Function in Women with a History of Puerperal Bipolar Disorder J Psychopharmacol, June 1, 2003; 17(2): 204 - 209. [Abstract] [PDF]

				W. S. Evans, S. M. Anderson, L. T. Hull, P. P. Azimi, C. Y. Bowers, and J. D. Veldhuis Continuous 24-Hour Intravenous Infusion of Recombinant Human Growth Hormone (GH)-Releasing Hormone-(1-44)-Amide Augments Pulsatile, Entropic, and Daily Rhythmic GH Secretion in Postmenopausal Women Equally in the Estrogen-Withdrawn and Estrogen-Supplemented States J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 700 - 712. [Abstract] [Full Text]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]

				P. Ovesen, N. Vahl, S. Fisker, J. D. Veldhuis, J. S. Christiansen, and J. O. L. Jørgensen Increased Pulsatile, But Not Basal, Growth Hormone Secretion Rates and Plasma Insulin-Like Growth Factor I Levels during the Periovulatory Interval in Normal Women J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1662 - 1667. [Abstract] [Full Text]

				D. A. Fryburg, A. Weltman, L. A. Jahn, J. Y. Weltman, E. Samojlik, R. L. Hintz, and J. D. Veldhuis Short-Term Modulation of the Androgen Milieu Alters Pulsatile, But Not Exercise- or Growth Hormone (GH)-Releasing Hormone-Stimulated GH Secretion in Healthy Men: Impact of Gonadal Steroid and GH Secretory Changes on Metabolic Outcomes J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3710 - 3719. [Abstract] [Full Text] [PDF]